Study on safety and efficacy of cetuximab in locally advanced, recurrent and/or metastatic oral cancer
- Conditions
- Oral cancer
- Registration Number
- JPRN-UMIN000020218
- Lead Sponsor
- agasaki University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 300
Not provided
Patients also applicable in one of the following are excluded as a target. 1. Cases with cetuximab treatment to December 20, 2012 or earlier. 2. Cases with complications in life prognosis in addition to oral cancer. 3. Cases with active double cancer. However, gastric cancer was cured by carcinoma in situ, or endoscopic mucosal resection that is judged to be cured with local treatment, esophageal cancer, colorectal cancer, such as pM it is not included in the activities of the overlapping cancer. 4. Other, patients principal investigator has determined to be inappropriate as a subject.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Adverse events, 1-year progression-free survival and 1-year survival rate.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.